scholarly journals Endogenous Secretory Receptor for Advanced Glycation End Products Is Associated With Low Serum Interleukin-1 Receptor Antagonist and Elevated IL-6 in Older Community-Dwelling Adults

2011 ◽  
Vol 66A (4) ◽  
pp. 437-443 ◽  
Author(s):  
C. L. Crasto ◽  
R. D. Semba ◽  
K. Sun ◽  
M. Dalal ◽  
A. M. Corsi ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Advanced Glycation End Products ◽  
Interleukin 1 ◽  
Community Dwelling ◽  
Advanced Glycation ◽  
Interleukin 1 Receptor Antagonist ◽  
Glycation End Products ◽  
End Products ◽  
Low Serum

scholarly journals Elevated level of the soluble receptor for advanced glycation end-products involved in sarcopenia: an observational study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Shou-En Wu ◽  
Yi-Lin Chiu ◽  
Tung-Wei Kao ◽  
Wei-Liang Chen
Keyword(s):  
Muscle Mass ◽  
Advanced Glycation End Products ◽  
Community Dwelling ◽  
Enzyme Linked Immunosorbent Assay ◽  
Health Examination ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Srage Level ◽  
Glycation End Products ◽  
End Products

Abstract Background The soluble receptor for advanced glycation end products (sRAGE) has been proposed to serve as a marker for disease severity, but its role in sarcopenia, an age-related progressive loss of muscle mass and function, remains elusive. This study examines the association between sRAGE and sarcopenia. Methods A total of 314 community-dwelling elderly adults who had their health examination at Tri-Service General Hospital from 2017 to 2019 underwent protein analysis with enzyme-linked immunosorbent assay. The relationship with sarcopenia and its detailed information, including components and diagnosis status, were examined using linear and logistic regressions. Results As for sarcopenia components, low muscle mass (β = 162.8, p = 0.012) and strength (β = 181.31, p = 0.011) were significantly correlated with sRAGE, but not low gait speed (p = 0.066). With regard to disease status, confirmed sarcopenia (β = 436.93, p < 0.001), but not probable (p = 0.448) or severe sarcopenia (p = 0.488), was significantly correlated with sRAGE. In addition, females revealed a stronger association with sRAGE level by showing significant correlations with low muscle mass (β = 221.72, p = 0.014) and low muscle strength (β = 208.68, p = 0.043). Conclusions sRAGE level showed a positive association with sarcopenia, illustrating its involvement in the evolution of sarcopenia. This association is more evident in female groups, which may be attributed to the loss of protection from estrogen in postmenopausal women. Utilizing sRAGE level as a prospective marker for sarcopenia deserves further investigation in future studies.

scholarly journals Mushroom Intake and Advanced Glycation End Products in the Skin among Community-Dwelling Elderly Subjects: Preliminary Data

2017 ◽  
Vol 2 ◽  
pp. 8-11 ◽  
Author(s):  
Yaeko Kawaguchi ◽  
Shinsuke Nirengi ◽  
Kazuhiko Kotani ◽  
Junichiro Somei ◽  
Takuya Kawamoto ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Preliminary Data ◽  
Community Dwelling ◽  
Elderly Subjects ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Protective effects against memory impairment induced by methylglyoxal in mice co-treated with FPS-ZM1, an advanced glycation end products receptor antagonist

2020 ◽  
Vol 80 (4) ◽  
pp. 364-374 ◽  
Author(s):  
Jozimar Carlos Szczepanik ◽  
Abel Freitas Garcia ◽  
Gudrian Ricardo Lopes de Almeida ◽  
Mauricio Peña Cunha ◽  
Alcir Luiz Dafre
Keyword(s):  
Receptor Antagonist ◽  
Advanced Glycation End Products ◽  
Memory Impairment ◽  
Protective Effects ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Fingertip advanced glycation end products and psychotic symptoms among adolescents

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Mitsuhiro Miyashita ◽  
Syudo Yamasaki ◽  
Shuntaro Ando ◽  
Kazuhiro Suzuki ◽  
Kazuya Toriumi ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Multinomial Logistic Regression ◽  
Structured Interview ◽  
Community Dwelling ◽  
Psychotic Symptoms ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Drug Naïve

AbstractCase control studies have suggested that advanced glycation end products play a key role in the pathophysiology of chronic schizophrenia. However, the longitudinal association between advanced glycation end products and psychotic symptoms among drug-naïve adolescents remains unclear. This study examined whether advanced glycation end products could predict the trajectory of psychotic symptoms in drug-naive adolescents using data from prospective population-based biomarker subsample study of the Tokyo Teen Cohort. A total of 277 community-dwelling adolescents aged 13 years without antipsychotic medication were analyzed. Fingertip advanced glycation end products were measured in adolescents using noninvasive technology that can be used quickly. The trajectory of psychotic symptoms in a 12-month follow-up was assessed by experienced psychiatrists using a semi-structured interview. Of the 277 participants, 13 (4.7%) experienced persistent psychotic symptoms (psychotic symptoms at baseline and follow-up), 65 (23.5%) experienced transient psychotic symptoms (psychotic symptoms at baseline or follow-up), and 199 (71.8%) did not have psychotic symptoms. Multinomial logistic regression analysis adjusted for age and sex revealed that baseline fingertip advanced glycation end products might predict the risk of persistent psychotic symptoms (odds ratio = 1.68; 95% confidence interval, 1.05–2.69; P = 0.03). Altogether, fingertip advanced glycation end products potentially predicted the trajectory of psychotic symptoms among drug-naive adolescents, which indicated its involvement in the pathophysiology of early psychosis. Further studies are required to identify strategies to reduce adolescent advanced glycation end products, which may contribute to preventing the onset of psychosis.

scholarly journals Defective Glyoxalase 1 Contributes to Pathogenic Inflammation in Cystic Fibrosis

Vaccines ◽  
2021 ◽  
Vol 9 (11) ◽  
pp. 1311
Author(s):  
Marilena Pariano ◽  
Claudio Costantini ◽  
Ilaria Santarelli ◽  
Matteo Puccetti ◽  
Stefano Giovagnoli ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Advanced Glycation End Products ◽  
Interleukin 1 ◽  
Autosomal Recessive Disorder ◽  
Advanced Glycation ◽  
Glyoxalase 1 ◽  
Multiple Organs ◽  
Glycation End Products ◽  
End Products ◽  
Inflammatory State

Cystic fibrosis (CF) is an autosomal recessive disorder that affects multiple organs, although a decline in respiratory function represents the major cause of morbidity and mortality. The airways of CF patients are characterized by a chronic inflammatory state to which the receptor for advanced glycation end-products greatly contributes. Glyoxalase 1 (GLO1) is the major enzyme metabolizing methylglyoxal, a potent precursor of advanced glycation end-products. Its role in CF has never been investigated. We herein resorted to murine and human preclinical models of CF to define the contribution of GLO1 to inflammatory pathology. We found that the expression and activity of GLO1, measured by real-time PCR and Western blot or a specific spectrophotometric assay, respectively, are defective in mice and human bronchial cells from CF patients exposed to Aspergillus fumigatus, a common pathogen in CF, but could be restored upon blockade of interleukin-1 receptor signaling by anakinra in mice. This study suggests that GLO1 contributes to pathology in CF and may be potentially targeted to mitigate inflammation.

Sign in / Sign up

Export Citation Format

Share Document